65 completed. 65 Phase 1, 16 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 65 | Completed 65 |
| Phase 2 | 16 | Completed 16 |
Follow Streptococcal Infections: new trials by email Literature Review of Streptococcal Infections trials Research Report on Streptococcal Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Learn About How Safe and Effective is 20vPnC and 13vPnC Vaccines in Chinese Adults 20vPnC, 13vPnC - Pneumococcal Disease | Phase 1 | Completed | Pfizer | 400 | 2025-07-06 | 2026-02-25 |
| Clinical Trial of PCV24 in Adults Aged ≥18 Years Sinovac Low-dosage PCV24, Sinovac Middle-dosage PCV24, Sinovac High-dosage PCV24 - Pneumococcal Infectious Disease | Phase 1 / Phase 2 | Completed | Sinovac Life Sciences Co., Ltd. | 385 | 2025-06-18 | 2026-04-21 |
| Clinical Trial of PCV24 in Children Aged 2-17 Years Sinovac PCV24 formulation 1, Sinovac PCV24 formulation 2, Prevenar13® - Pneumococcal Infectious Disease | Phase 1 | Completed | Sinovac Life Sciences Co., Ltd. | 119 | 2024-09-07 | 2026-01-28 |
| Study of Gamma PN3 in the Elderly Gamma PN3, Prevnar - Pneumonia, Pneumococcal | Phase 1 | Completed | GPN Vaccines | 105 | 2024-08-26 | 2025-05-11 |
| Clinical Trial of PCV24 in Adults Sinovac PCV24 formulation 1, Sinovac PCV24 formulation 2, Pneumovax® - Pneumococcal Infectious Disease | Phase 1 | Completed | Sinovac Life Sciences Co., Ltd. | 170 | 2024-06-21 | 2025-04-16 |
| Phase I Clinical Trial of PCV24 in Children Aged 2 Months (Minimum 6 Weeks) to 17 Years PCV24 formulation 1, PCV24 formulation 2, 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine - Pneumococcal Infectious Disease | Phase 1 | Completed | Reinovax Biologics Co., LTD | 230 | 2024-04-27 | 2026-08-17 |
| A Phase 1b Clinical Trial of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine Sinovac PCV13, PREVNAR 13 - Pneumococcal Infectious Disease | Phase 1 | Completed | Sinovac Research and Development Co., Ltd. | 140 | 2024-01-04 | 2026-01-28 |
| A Study to Learn About the Safety and Immune Response of a New Pneumococcal Vaccine in Adults Multivalent Pneumococcal Vaccine - Formulation 1, Multivalent Pneumococcal Vaccine - Formulation 2, 20-valent pneumococcal conjugate vaccine (20vPnC) - Pneumococcal Disease | Phase 1 / Phase 2 | Completed | Pfizer | 1710 | 2023-12-20 | 2026-09-25 |
| Phase I Clinical Trial of PCV24 in People Aged 18 Years and Older Reinovax PCV24 formulation 1, Reinovax PCV24 formulation 2, PPSV23 - Pneumococcal Infectious Disease | Phase 1 | Completed | Reinovax Biologics Co., LTD | 240 | 2023-11-19 | 2024-11-07 |
| Extension Safety and Immunogenicity Study of GPNV-001 Gamma-PN3, Pneumovax-23, Prevenar-13 - Pneumococcal Infections | Phase 1 / Phase 2 | Completed | GPN Vaccines | 60 | 2023-07-17 | 2024-12-18 |
| A Study to Learn About a Type of Pneumococcal Vaccine With a New Ingredient (PF-07872411) Intended to Enhance the Effects of the Vaccine Which is Given to Adults Low dose multivalent pneumococcal conjugate vaccine formulation A, Low dose multivalent pneumococcal conjugate vaccine formulation B, Low dose of multivalent pneumococcal conjugate vaccine control - Pneumococcal Disease | Phase 1 | Completed | Pfizer | 90 | 2023-04-19 | 2024-07-29 |
| Study to Evaluate the Safety, Tolerability and Immunogenicity of Three Doses of GBS Vaccine in Elderly Participants GBS-NN/NN2, Placebo - Group B Streptococcal Infections | Phase 1 | Completed | Minervax ApS | 90 | 2023-03-01 | 2025-09-05 |
| Safety, Tolerability and Immunogenicity of an Inactivated Whole-cell Pneumococcal Vaccine Gamma-PN3. Gamma-PN3, Prevenar-13, Pneumovax-23 - Pneumococcal Infections | Phase 1 | Completed | GPN Vaccines | 118 | 2023-01-16 | 2024-09-05 |
| Safety and Immunogenicity Study of a 13-valent Pneumococcal Polysaccharide Conjugate Vaccine Investigational 13-valent Pneumococcal Polysaccharide Conjugate Vaccine, Control 13-valent Pneumococcal Polysaccharide Conjugate Vaccine ( WALVAX PCV13), Control 13-valent Pneumococcal Polysaccharide Conjugate Vaccine ( Pfizer PCV13) - Pneumococcal Infections | Phase 1 | Completed | Sinovac Life Sciences Co., Ltd. | 310 | 2023-01-03 | 2026-01-28 |
| A Trial of a Peptide-based Group A Streptococcal (GAS) Vaccine Candidate in Healthy Individuals. p*17-K4S2, J8-K4S2, Rabavert vaccine - Group A Streptococcal Infection | Phase 1 / Phase 2 | Completed | University of Alberta | 30 | 2022-11-07 | 2025-05-28 |
| Safety and Immunogenicity of Pneumococcal Conjugate Formulations in Healthy Adults 18 Through 49 Years of Age Candidate-1, Candidate-2, Candidate-3 - Pneumococcal Disease | Phase 1 | Completed | Pfizer | 394 | 2022-08-15 | 2024-04-18 |
| Safety, Tolerability, and Immunogenicity of a Polyvalent Pneumococcal Conjugate Vaccine (V116) in Japanese Adults (V116-002) V116, PNEUMOVAX™23 - Pneumococcal Infection | Phase 1 | Completed | Merck Sharp & Dohme LLC | 102 | 2021-02-04 | 2023-10-04 |
| A Study to Assess the Safety, Tolerability and Immunogenicity of ASP3772, a Pneumococcal Vaccine, in Toddlers 12 to 15 Months of Age in Comparison to an Active Comparator ASP3772, PCV13 - Healthy Volunteers, Pneumococcal Disease | Phase 1 | Completed | Affinivax, Inc. | 75 | 2020-09-22 | 2022-06-06 |
| Safety and Immunogenicity of the 'EuPCV15' in Healthy Korean Adults EuPCV15, Prevenar13 - Pneumococcal Disease | Phase 1 | Completed | EuBiologics Co.,Ltd | 60 | 2020-05-28 | 2021-10-07 |
| Phase I Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine（CRM197,TT）, 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine - Pneumococcal Infections, Streptococcal Infections | Phase 1 | Completed | CanSino Biologics Inc. | 237 | 2020-05-18 | 2022-10-31 |
Showing 20 of 65. Sign in to see all of them.
Pneumococcal Infections (44) · Pneumonia, Pneumococcal (8) · Pneumonia (4) · Staphylococcal Skin Infections (4) · Bacterial Infections (2) · Cellulitis (2) · HIV Infections (2) · Pneumonia, Bacterial (2) · AIDS-Related Complex (1) · Acquired Immunodeficiency Syndrome (1) · Dental Caries (1) · Gram-Positive Bacterial Infections (1) · Haemophilus Infections (1) · Obesity (1)
Bacterial Infections and Mycoses (65) · Infections (65) · Gram-Positive Bacterial Infections (64) · Bacterial Infections (63) · Lung Diseases (13) · Respiratory Tract Diseases (13) · Respiratory Tract Infections (13) · Pneumonia (9) · Pneumonia, Bacterial (7) · Pneumococcal Infections (5) · Skin and Connective Tissue Diseases (5) · Skin Diseases (4) · Skin Diseases, Bacterial (4) · Skin Diseases, Infectious (4)
13-valent pneumococcal vaccine (13) · 23-valent pneumococcal capsular polysaccharide vaccine (8) · Heptavalent Pneumococcal Conjugate Vaccine (8) · Pneumococcal Vaccines (8) · ceftobiprole (4) · PHiD-CV vaccine (2) · Sodium Chloride (2) · Vaccines, Combined (2) · 10-valent pneumococcal conjugate vaccine (1) · Epinephrine (1) · Pentavac (1) · Saline Solution (1) · Tetanus Toxoid (1)
Pfizer (7) · GlaxoSmithKline (6) · Merck Sharp & Dohme LLC (6) · Basilea Pharmaceutica (4) · Sinovac Life Sciences Co., Ltd. (4) · GPN Vaccines (3) · Centers for Disease Control and Prevention (2) · Minervax ApS (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · PATH (2) · Reinovax Biologics Co., LTD (2) · Sanofi (2) · Sanofi Pasteur, a Sanofi Company (2) · Wyeth is now a wholly owned subsidiary of Pfizer (2) · Affinivax, Inc. (1)
United States (14) · China (10) · Belgium (5) · Australia (4) · Germany (3) · South Korea (3) · Switzerland (3) · Bangladesh (2) · Canada (2) · Japan (2) · Kenya (2) · Sweden (2) · United Kingdom (2) · Brazil (1) · Finland (1)
Geoff Kitson (2) · Kai Chu (2) · Andrew C Steer, MBBS,MPH,PhD (1) · Anthony Scott, MD, PhD (1) · Christopher Bailey, Bsc, PhD (1) · Ed Clarke, MD PhD (1) · Evelyn Hatzenbichler, PhD (1) · Harry L Keyserling, MD (1) · Itamara LI Neves, PhD (1)
PMID 30689507, PMID 10212363, PMID 1053919, PMID 10709851, PMID 10717828, PMID 10895619, PMID 11139785, PMID 11199555, PMID 11321382, PMID 11409642, PMID 1157366, PMID 1170757, PMID 11875603, PMID 12436828, PMID 12685620, PMID 12723166, PMID 12767443, PMID 12873775, PMID 13263433, PMID 14446037, PMID 1452871, PMID 14894244, PMID 15190533, PMID 15851928, PMID 15882530, PMID 15917682, PMID 16022946, PMID 16175029, PMID 16175030, PMID 16648419, PMID 16695846, PMID 17391816, PMID 1812051, PMID 18799552, PMID 19522655, PMID 1984216, PMID 20435707, PMID 2213464, PMID 22353593, PMID 2263330, PMID 23123106, PMID 23131206, PMID 23153437, PMID 23300160, PMID 23535358, PMID 2365491, PMID 23967126, PMID 24176494, PMID 24599529, PMID 24607003
2009 (1), 2015 (1), 2017 (1), 2019 (1)